Autopsy report · NCT00573131
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Cause of deathFutility
“OncoGel did not show any impact on overall tumor response”
Life of this trial
- Registered 1 month before it started.
- Ran for about 2 years 10 months before it stopped.
- 137 participants enrolled.
- Results were posted on the registry 3 years 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Boston Scientific Corporation
- Sponsor type
- Industry
- Conditions
- Esophageal Cancer; Adenocarcinoma of the Esophagus; Squamous Cell Carcinoma
- Interventions
- OncoGel (Paclitaxel gel); cisplatin; 5-FU; radiation therapy; esophageal resection
- Participants
- 137
- Sites
- 20
- Countries
- Czechia, India, Poland, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.